At a glance
Side-by-side comparison
| Metric |
CURE
Global X S&P Biotech ETF
|
IXJ
iShares Global Healthcare ETF
|
IXI
iShares Global Consumer Staples ETF
|
DRUG
BetaShares Global Healthcare ETF - Currency Hedged
|
|---|---|---|---|---|
| Snapshot | ||||
| Provider |
Global X
|
iShares
|
iShares
|
BetaShares
|
| Tracks index |
S&P Biotechnology Select Industry Index
|
S&P Global 1200 Health Care Sector Index
|
S&P Global 1200 Consumer Staples Sector Index
|
Nasdaq Global ex-Australia Healthcare Hedged AUD Index
|
| Categories |
US, Thematic
|
Intl, Thematic, Market-Cap
|
Intl, Thematic, Market-Cap
|
Intl, Thematic
|
| Listed since |
2021 (5 yrs)
|
2007 (19 yrs)
|
2007 (19 yrs)
|
—
|
| Fund size (AUM) |
$50m
|
$1.5bn
|
$128m
|
$172m
|
| Cost & income | ||||
| Management fee |
0.45%
|
0.4%
|
0.4%
|
0.57%
|
| Dividend yield |
0%
|
1.56%
|
2.11%
|
3.9%
|
| Franking |
0%
|
0%
|
0%
|
0%
|
| Turnover |
35%
|
5%
|
5%
|
—
|
| Tax drag | 0.84% | 0.62% | 0.8% | 1.25% |
| Returns |
Tax bracket
|
|||
| 1-year return |
49.9%
net
|
11.2%
net
|
-1.2%
net
|
17.2%
net
|
| 3-year return |
25.8%
net
|
6.1%
net
|
4.4%
net
|
7.3%
net
|
| 5-year return |
5.3%
net
|
6.1%
net
|
4.7%
net
|
5.1%
net
|
| 10-year return |
—
|
9.8%
net
|
6%
net
|
8.2%
net
|
| Risk | ||||
| Volatility (3y) |
25.1%
|
12.6%
|
9.2%
|
12.6%
|
| Volatility (5y) |
24.8%
|
12.2%
|
10.8%
|
13.1%
|
| Volatility (10y) |
—
|
11.5%
|
10.7%
|
12.9%
|
| Sharpe ratio (3y) |
0.88
|
0.2
|
—
|
0.3
|
| Sharpe ratio (5y) |
0.19
|
0.27
|
0.16
|
0.19
|
| Sharpe ratio (10y) |
—
|
0.67
|
0.39
|
0.5
|
| Bid/ask spread |
—
|
—
|
—
|
—
|
marks the strongest fund in each row. “net” shows the after-tax return at your selected bracket. “—” means we don’t have that data point yet.
Each fund at a glance
- Top-2% returns over 1 year (7th of 318 ETFs we track).
- Cheaper alternatives exist: IXJ and IXI.
- Low-cost: a 0.4% management fee keeps more of the return in your pocket.
- Has lagged most peers over 3 years (176th of 236).
- Low-cost: a 0.4% management fee keeps more of the return in your pocket.
- Has lagged most peers over 3 years (194th of 236).
- Top-15% returns over 1 year (49th of 318 ETFs we track).
- Pays a useful 3.9% income yield.
- Pricier than similar ETFs, which average around 0.46%.
Frequently Asked Questions
CURE, IXJ, IXI, and DRUG are 4 Australian-listed ETFs we compare side by side. IXJ carries the lowest management fee (0.4%). Over 10 years, IXJ has delivered the highest total return (9.8% a year). The table above breaks down fees, returns, income and risk for each.
IXJ has the lowest management fee at 0.4% a year, versus CURE 0.45%, IXI 0.4%, and DRUG 0.57%.
Over the past 10 years, IXJ has delivered the highest total return at 9.8% a year. Past performance is not a reliable indicator of future returns.
DRUG pays the highest at 3.9%. Remember distributions are taxed each year at your marginal rate.
IXJ is the largest fund by assets ($1.5bn). Larger funds are typically more liquid and trade on tighter spreads.
Related comparisons
General information only, generated from each fund's published data — not personal financial advice. Past performance is not a reliable indicator of future returns. Consider your own circumstances or seek licensed advice before investing.